Aura Enters PR Campaign in Western Canada & Grants Options to Director
January 18 2019 - 7:00AM
Aura Health Inc. (the "
Company" or
“
Aura”) (
CSE:BUZZ) is pleased to
announce that the Company has entered into a strategic PR campaign
in Western Canada with R. Ian Cochrane. Mr. Cochrane brings three
decades of marketing small and microcap companies in Western
Canada. He will be an important asset in increasing the wherewithal
of Aura in the western provinces.
Aura will compensate Mr. Cochrane by granting
350,000 stock options of the Company (the
“Options”) on January 17, 2019 exercisable at
$0.235. 200,000 Options shall vest immediately with 150,000 Options
to vest on April 17, 2019. The Options shall expire on January 17,
2021.
The company is also pleased to announce the
grant of 200,000 Options to Joel Freudman, Aura’s independent
director and Chair of the Board of Director’s Audit Committee, on
January 17, 2019. Since entering into the role in October 2018, Mr.
Freudman has played an important role in guiding the company in
audit and finance related issues. The Options shall be exercisable
at $0.235, will vest immediately, and expire on January 17,
2021.
About Aura Health Inc.
Aura Health is building an international network
of vertically integrated cannabis assets. Through an established
product line of cannabis-infused edible products and oil extracts,
Aura is dedicated to building a high margin downstream business in
the medical marijuana sector. The company holds convertible debt
that converts to 54% equity of HolyCanna, a cultivation and nursery
license holder in Israel. The company also owns a 30% interest in
four medical marijuana clinics in the U.S. Sun Belt.
For further information, please contact:
Daniel Cohen, CEO Aura Health Inc. (647)
202-1824
David Posner, ChairmanAura Health Inc. (647)
985-6727
Caution Regarding Forward-Looking
Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT
REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
This news release may contain forward-looking
statements and information based on current expectations. These
statements should not be read as guarantees of future performance
or results. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements. Such statements include submission of
the relevant documentation within the required timeframe and to the
satisfaction of the relevant regulators, completing the acquisition
of the applicable real estate and raising sufficient financing to
complete the Company's business strategy. There is no certainty
that any of these events will occur. Although such statements are
based on management's reasonable assumptions, there can be no
assurance that such assumptions will prove to be correct. We assume
no responsibility to update or revise them to reflect new events or
circumstances.
The Company's securities have not been
registered under the U.S. Securities Act of 1933, as amended (the
"U.S. Securities Act"), or applicable state securities laws, and
may not be offered or sold to, or for the account or benefit of,
persons in the United States or "U.S. Persons", as such term is
defined in Regulation S under the U.S. Securities Act, absent
registration or an applicable exemption from such registration
requirements. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy nor shall there be any
sale of the securities in the United States or any jurisdiction in
which such offer, solicitation or sale would be unlawful.
Additionally, there are known and unknown risk
factors which could cause the Company's actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. All forward-looking
information herein is qualified in its entirety by this cautionary
statement, and the Company disclaims any obligation to revise or
update any such forward-looking information or to publicly announce
the result of any revisions to any of the forward-looking
information contained herein to reflect future results, events or
developments, except as required by law.
Pharmadrug (CSE:BUZZ)
Historical Stock Chart
From Nov 2024 to Dec 2024
Pharmadrug (CSE:BUZZ)
Historical Stock Chart
From Dec 2023 to Dec 2024